Summary
Signal counts
Assets tracked: 2
Watchlist assets: 2
Registry stop assets: 0
Sponsor overview
Suzhou Zelgen Biopharmaceuticals Co.,
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT07258121 | https://clinicaltrials.gov/study/NCT06237400
Assets